[Intestinal excretion of nystatin during and after oral administration to newborn infants at risk].
The concentrations of nystatin excreted with faeces during and after oral application of 3 x 150,000 IU/d, either continuously for 14-21 days or every second day were determined in 42 newborns at risk by means of a bioassay (agar diffusion test). Results indicate that nystatin is distributed heterogeneously in the gastrointestinal tract. The excretion occurs discontinuously. 24 to 48 h after beginning of therapy there were effective concentrations of nystatin in the faeces. The daily application of 3 x 150,000 IU nystatin is recommended.
Blaschke-Hellmessen
R
R
Institut für Medizinische Mikrobiologie, Medizinischen Akademie Carl Gustav Carus, Dresden.
Pannwitz
U
U
Schwarze
R
R
D001682:Biological Availability; D002179:Candidiasis, Cutaneous / Q000097:blood* / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000097:blood* / Q000188:drug therapy; D003963:Diaper Rash / Q000097:blood* / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005243:Feces / Q000737:chemistry; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood* / Q000188:drug therapy; D008657:Metabolic Clearance Rate; D009761:Nystatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012307:Risk Factors
D009761:Nystatin
Zur intestinalen Ausscheidung von Nystatin während und nach oraler Applikation bei Risikoneugeborenen.